SIGA
SIGA clinical trials: SIGA TECHNOLOGIES INC
Every trial on ClinicalTrials.gov where SIGA TECHNOLOGIES INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 9
- As lead sponsor
- 2
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
SIGA on the catalyst calendar · SIGA registry changes
- Primary completion May 12, 2023ActualPhase 3NCT04971109Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 DaysSIGA Technologies · SmallpoxCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2027Sponsor estimatePhase 2NCT04957485Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSSIGA Technologies · SmallpoxActive, not recruitingSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2022ActualPhase 4NCT04485039Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate BindersSIGA Technologies · SmallpoxCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2019ActualPhase 4NCT04392739Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KGSIGA Technologies · SmallpoxCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2024Sponsor estimateNo phase registeredNCT03972111A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With SmallpoxSIGA Technologies · SmallpoxWithdrawnSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 24, 2016ActualPhase 3NCT02474589A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound TecovirimatSIGA Technologies · SmallpoxCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2010ActualPhase 2NCT00907803Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246SIGA Technologies · Orthopoxviral DiseaseCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2008ActualPhase 1NCT00728689Phase I Trial of an Investigational Small Pox MedicationSIGA Technologies · Orthopoxviral DiseaseCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2008ActualPhase 1NCT00431951Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy VolunteersSIGA Technologies · HealthyCompletedSIGALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 23, 2024ActualPhase 3NCT05534984Study of Tecovirimat for Human Mpox VirusNational Institute of Allergy and Infectious Diseases (NIAID) · MPOXTerminatedSIGACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05380752Tecovirimat Intravenous Treatment for Orthopox Virus ExposureU.S. Army Medical Research and Development Command · Orthopox Virus InfectionNo longer availableSIGACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner